Composition of thymic peptide alpha 1 and thymopeptide-5 and preparation method thereof

A technology of composition and thymosin, which is applied in the field of composition of thymosin α1 and thymopentin, can solve the problems of low immune function, transfer, and low efficiency, and achieve rapid dissolution, good stability, and less side effects

Active Publication Date: 2010-03-31
HAINAN ZHONGHE PHARM CO LTD
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most patients with cancer have developed to an advanced stage and have metastases at the time of diagnosis, so that surgical resection is impossible, and they can only be treated with radiotherapy or chemoth

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition of thymic peptide alpha 1 and thymopeptide-5 and preparation method thereof
  • Composition of thymic peptide alpha 1 and thymopeptide-5 and preparation method thereof
  • Composition of thymic peptide alpha 1 and thymopeptide-5 and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Example 1 Preparation of Thymosin α1 and Thymopentin Composition Injection

[0065] 1. Prescription

[0066] Prescription of Thymosin α1 and Thymopentin Composition (1)

[0067] Thymosin α1 1.6g

[0068] Thymopentin 1.0g

[0069] Mannitol 50g

[0070] Sodium dihydrogen phosphate 0.796g

[0071] Disodium hydrogen phosphate 1.755g

[0072] Add water for injection to 1000ml

[0073]

[0074] A total of 1000 bottles were made

[0075] Prescription of Thymosin α1 and Thymopentin Composition (2)

[0076] Thymosin α1 1.0g

[0077] Thymopentin 1.0g

[0078] Mannitol 25g

[0079] Sodium acetate 0.1g

[0080] Add water for injection to 1000ml

[0081]

[0082] Adjust the pH value to 5.5-7.5 with acetic acid and make a total of 1000 bottles

[0083] Prescription of Thymosin α1 and Thymopentin Composition (3)

[0084] Thymosin α1 1.6g

[0085] Thymopentin 1.6g

[0086]...

Embodiment 2

[0110] Embodiment 2 Preparation of thymosin α1 and thymopentin composition freeze-dried powder injection

[0111] 1. Prescription

[0112] Prescription of Thymosin α1 and Thymopentin Composition (1)

[0113] Thymosin α1 1.6g

[0114] Thymopentin 0.8g

[0115] Mannitol 50g

[0116] Sodium dihydrogen phosphate 0.796g

[0117] Disodium hydrogen phosphate 1.755g

[0118] Add water for injection to 1000ml

[0119]

[0120] A total of 1000 bottles were made

[0121] Prescription of Thymosin α1 and Thymopentin Composition (2)

[0122] Thymosin α1 0.5g

[0123] Thymopentin 1.0g

[0124] Mannitol 25g

[0125] Sodium acetate 0.1g

[0126] Add water for injection to 1000ml

[0127]

[0128] Adjust the pH value to 5.5-7.5 with acetic acid and make a total of 1000 bottles

[0129] Prescription of Thymosin α1 and Thymopentin Composition (3)

[0130] Thymosin α1 1.0g

[0131] Thymopentin 2....

Embodiment 3

[0154] The preparation of embodiment 3 thymosin alpha 1 and thymopentin composition

[0155] The dose of thymosin α1 is 0.1 mg; the dose of thymopentin is 0.1 mg.

[0156] The preparation method is the same as claim 1

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a composition of thymic peptide alpha 1 and thymopeptide-5 and a preparation method thereof. The compound preparation can be used for the treatment of chronic hepatitis B andvarious diseases with damaged immunological functions and the auxiliary treatment of tumours. The composition mainly comprises 0.1-10mg of thymic peptide alpha 1 and 0.1-100mg of thymopeptide-5. Simultaneously, proper auxiliary materials are added into the composition to prepare injection liquid or a freeze-drying medicament form. The composition prepared according to the proportion has obvious synergy action and can reach a better curative effect dose ratio for the treatment of the chronic hepatitis B and various diseases with damaged immunological functions and the auxiliary treatment of thetumours.

Description

Technical field: [0001] The invention relates to a composition of thymosin alpha 1 and thymopentin and a preparation method thereof. The compound preparation can be used for treating chronic hepatitis B, various diseases with impaired immune function and adjuvant treatment of tumors. Background technique: [0002] Hepatitis B is the most common infectious liver disease in the world. It is caused by the hepatitis B virus (HBV), which can be transmitted through blood, unprotected sex, sharing needles, and from infected mothers to newborn babies during delivery. Because patients with hepatitis B do not know that they have been infected by the virus, they often pass the virus on to people who have close contact with them, which leads to widespread transmission. There are currently about 400 million chronic hepatitis B virus infected people in the world. According to the survey results released by the Ministry of Health in 2008, there are still about 93 million HBsAg carriers in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61P1/16A61P31/20A61P37/04A61P35/00A61K38/08
Inventor 崔学云周宗贞凌振宏宗永斌陈振博彭利洪
Owner HAINAN ZHONGHE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap